# Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation

> **NCT01919450** · PHASE4 · COMPLETED · sponsor: **Timothy M. Bateman, MD** · enrollment: 80 (actual)

## Conditions studied

- Myocardial Blood Flow Reserve

## Interventions

- **DRUG:** Regadenoson
- **RADIATION:** Rubidium-82

## Key facts

- **NCT ID:** NCT01919450
- **Lead sponsor:** Timothy M. Bateman, MD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2018-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01919450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01919450, "Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01919450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*